Patents by Inventor Dietrich BOESE

Dietrich BOESE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
    Publication number: 20230374021
    Abstract: The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) wherein the groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: February 10, 2023
    Publication date: November 23, 2023
    Inventors: Birgit WILDING, Dietrich BOESE, Harald ENGELHARDT, Julian FUCHS, Ralph NEUMUELLER, Mark PETRONCZKI, Dirk SCHARN, Matthias TREU
  • [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
    Publication number: 20230126204
    Abstract: The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) wherein the R groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: February 1, 2021
    Publication date: April 27, 2023
    Inventors: Birgit WILDING, Dietrich BOESE, Harald ENGELHARDT, Julian FUCHS, Ralph NEUMUELLER, Mark PETRONCZKI, Dirk SCHARN, Matthias TREU
  • [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
    Publication number: 20230131720
    Abstract: The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) wherein the groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: February 1, 2021
    Publication date: April 27, 2023
    Inventors: Birgit WILDING, Dietrich BOESE, Harald ENGELHARDT, Julian FUCHS, Ralph NEUMUELLER, Mark PETRONCZKI, Dirk SCHARN, Matthias TREU
  • Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
    Patent number: 11608343
    Abstract: The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) wherein the groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: April 6, 2021
    Date of Patent: March 21, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Birgit Wilding, Dietrich Boese, Harald Engelhardt, Julian Fuchs, Ralph Neumueller, Mark Petronczki, Dirk Scharn, Matthias Treu
  • NEW MACROCYCLIC COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS
    Publication number: 20220380382
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R3, A, B and L and p and q have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: June 23, 2020
    Publication date: December 1, 2022
    Inventors: Harald ENGELHARDT, Dietrich BOESE
  • Benzimidazole compounds and derivatives as EGFR inhibitors
    Patent number: 11174245
    Abstract: The present invention encompasses compounds of formula (I) (I), wherein the groups R1 to R5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: November 16, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dietrich Boese, Georg Dahmann, Harald Engelhardt, Mark Petronczki, Dirk Scharn
  • [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS
    Publication number: 20210332054
    Abstract: The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) wherein the groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: April 6, 2021
    Publication date: October 28, 2021
    Inventors: Birgit WILDING, Dietrich BOESE, Harald ENGELHARDT, Julian FUCHS, Ralph NEUMUELLER, Mark PETRONCZKI, Dirk SCHARN, Matthias TREU
  • NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS
    Publication number: 20200377476
    Abstract: The present invention encompasses compounds of formula (I) (I), wherein the groups R1 to R5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: February 20, 2019
    Publication date: December 3, 2020
    Inventors: Dietrich BOESE, Georg DAHMANN, Harald ENGELHARDT, Mark PETRONCZKI, Dirk SCHARN